Shattuck Labs Inc Ordinary Shares STTK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if STTK is a good fit for your portfolio.
News
-
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
-
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
-
Shattuck Labs Announces Participation in Upcoming March Conferences
-
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
-
Thinking about buying stock in Avinger, Cloudflare, Backblaze, Shattuck Labs, or Beamr Imaging?
-
Shattuck Strikes Joint Development Deal With Japan's Ono Pharma
-
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
-
Thinking about buying stock in Notable Labs, Shattuck Labs, Medical Properties Trust, Blink Charging, or Spectaire Holdings?
Trading Information
- Previous Close Price
- $8.98
- Day Range
- $8.68–9.03
- 52-Week Range
- $1.33–11.11
- Bid/Ask
- $8.67 / $9.82
- Market Cap
- $424.42 Mil
- Volume/Avg
- 319,072 / 420,468
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 229.84
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 75
- Website
- https://www.shattucklabs.com
Comparables
Valuation
Metric
|
STTK
|
CLDX
|
TYRA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.92 | 5.47 | 3.45 |
Price/Sales | 229.84 | 295.42 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
STTK
CLDX
TYRA
Financial Strength
Metric
|
STTK
|
CLDX
|
TYRA
|
---|---|---|---|
Quick Ratio | 11.41 | 13.69 | 13.27 |
Current Ratio | 12.51 | 13.87 | 13.80 |
Interest Coverage | — | — | — |
Quick Ratio
STTK
CLDX
TYRA
Profitability
Metric
|
STTK
|
CLDX
|
TYRA
|
---|---|---|---|
Return on Assets (Normalized) | −48.33% | −30.49% | −22.50% |
Return on Equity (Normalized) | −54.85% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −56.35% | −32.85% | −27.79% |
Return on Assets
STTK
CLDX
TYRA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qkpwtqtbhc | Wgbnc | $570.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zxxvdcfz | Dqpbvq | $108.0 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dyrszgvn | Rcwyp | $105.6 Bil | |
MRNA
| Moderna Inc | Lqbsqycc | Zbf | $40.8 Bil | |
ARGX
| argenx SE ADR | Pxvtnjfw | Jpx | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Vbrwtcbff | Shx | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rxrwnbd | Szqsxqb | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vrcflnhs | Tjsqjg | $16.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lbvbdljl | Cxhzkw | $13.6 Bil | |
INCY
| Incyte Corp | Htdpbjjxx | Jgcwz | $12.8 Bil |